The dual control model: current status and future directions.

The Kinsey Institute for Research in Sex, Gender, and Reproduction, Indiana University, USA.
The Journal of Sex Research (Impact Factor: 2.53). 04/2009; 46(2-3):121-42. DOI: 10.1080/00224490902747222
Source: PubMed

ABSTRACT The Dual Control Model proposes that sexual responses involve an interaction between sexual excitatory and sexual inhibitory processes. The model further postulates that individuals vary in their propensity for both sexual excitation and sexual inhibition, and that such variations help us to understand much of the variability in human sexuality. The development of psychometrically validated instruments for measuring such propensities for men (Sexual Inhibition/Sexual Excitation Scales) and for women (Sexual Excitation/Sexual Inhibition Inventory for Women) is described. These measures show close to normal variability in both men and women, supporting the concept that "normal" levels of inhibition proneness are adaptive. The relevance of the model to sexual development, sexual desire, the effects of aging, sexual identity, and the relation between mood and sexuality are discussed, and the available evidence is reviewed. Particular attention is paid to gender differences and similarities in propensities for sexual excitation and inhibition. Research findings related to sexual problems, high-risk sexual behavior, and the relevance of this model to clinical management of such problems are also summarized. Last, ideas for future use and further development of the Dual Control Model are considered.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: There is growing recognition of female sexual dysfunction (FSD) as an important women's health concern. Despite an increased awareness of the pathophysiologic components to FSD, currently, there are no drugs approved for the most common sexual complaint in women-decreased sexual desire. In response to an overwhelming demand for therapy for FSD, several drugs are undergoing development and testing. Areas covered: The aim of this paper is to provide the latest data on pharmacological treatments for FSD currently in Phase I and II clinical trials. These include topical alprostadil, bremelanotide (BMT), intranasal testosterone (TBS-2), intravaginal dehydroepiandrosterone (DHEA), sublingual testosterone with sildenafil, apomorphine (APO), bupropprion and trazodone. It should be noted that the definitions of FSD have recently been revised in the diagnostic and statistical manual for mental disorders (DSM) 5, with merging of hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD) into female sexual interest/arousal disorder (FSIAD). However, it is noted that the majority of clinical trials discussed in this paper use the DSM IV-R diagnoses of HSDD and FSAD. Expert opinion: Medications in early phase trials show promise for the treatment of FSD. These therapies focus on treating many possible causes of FSD. Concerns over gender bias within the FDA need to be resolved given the need for new treatment options for FSD.
    Expert Opinion on Investigational Drugs 11/2014; 24(2):1-9. DOI:10.1517/13543784.2015.978283 · 5.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The theoretical proximity of the Dual-Control Model of the Sexual Response and the Reinforcement Sensitivity Theory predicts at least moderate-size correlations of measurements based on these models. However, sexual inhibition has also been claimed to be domain-specific, suggesting smaller-size correlations and superior prediction of sexual outcomes using measures of sexual inhibition and excitation, compared with generic measures. The aim of this study (N = 254) was to investigate the predictive validity of the Sexual Inhibition and Sexual Excitation Scale (SIS/SES) for, respectively, sexual and non-sexual risk behavior beyond prediction using scores on the Behavioral Inhibition and Behavioral Activation Scale (BIS/BAS). Both instruments, however, were found to contribute to the prediction of both types of risk behavior. The findings were interpreted as providing only partial support for the notion of domain specificity of sexual inhibition and excitation.
    Personality and Individual Differences 06/2015; 79. DOI:10.1016/j.paid.2015.01.048 · 1.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: U radu se opisuju postupci izradbe i provjere metrijskih svojstava višedimenzionalnog instrumenta za mjerenje zapreka uporabi muškoga kondoma. Konstrukcija i validacija provedena je na online uzorku osoba, poglavito studenata, između 18 i 30 godina (N=754). Provedene analize glavnih komponenata pokazale su postojanje pet međusobno povezanih dimenzija zapreka uporabi kondoma: (1) problemi vezani uz pregovaranje o uporabi kondoma i otpor partnera; (2) antierotski aspekti uporabe kondoma; (3) društvena (ne)poželjnost uporabe kondo-ma; (4) manjak samopouzdanja vezanog uz uporabu kondoma i (5) poteškoće vezane uz nabavku i nošenje kondoma. Višedi-menzionalnost skale testirana je i konfirmacijskom faktorskom analizom. Skalu prepreka uporabi kondoma (SPUK; k=27) i njezine komponente obilježava zadovoljavajuća pouzdanost, neovisna o spolu. Valjanost skale utvrđena je analizom povezanosti sa srodnim konstruktima. Autori vjeruju kako bi primjena skale mogla unaprijediti razumijevanje sporadične (nesustavne) upotrebe kondoma i tako poslužiti u izradbi programa prevencije HIV-a i drugih spolno prenosivih bolesti. Ključne riječi: kondom, zapreke uporabi kondoma, evaluacija instrumenta, mladi, odgovorno seksualno ponašanje Vanesa Benković, Hrvatsko društvo za farmakoekonomiku i ekonomiku zdravstva, Drage Stipca 10, 10 000 Zagreb, Hrvatska.
    Društvena Istraživanja / Journal for General Social Issues 10/2011; 20(3 (113)). DOI:10.5559/di.20.3.08 · 0.15 Impact Factor


Available from
Jun 1, 2014